Development and Interpretation of a Genomic Instability Derived IncRNAs Based Risk Signature as a Predictor of Prognosis for Clear Cell Renal Cell Carcinoma Patients

Huiying Yang†, Xiaoling Xiong† and Hua Li*

Department of Nephrology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, China

Background: Clear cell renal cell carcinoma (ccRCC) is a kind of frequently diagnosed cancer, leading to high death rate in patients. Genomic instability (GI) is regarded as playing indispensable roles in tumorigenesis and impacting the prognosis of patients. The aberrant regulation of long non-coding RNAs (lncRNAs) is a main cause of GI. We combined the somatic mutation profiles and expression profiles to identify GI derived IncRNAs (GID-lncRNAs) in ccRCC and developed a GID-lncRNAs based risk signature for prognosis prediction and medication guidance.

Methods: We decided cases with top 25% cumulative number of somatic mutations as genomically unstable (GU) group and last 25% as genomically stable (GS) group, and identified differentially expressed lncRNAs (GID-lncRNAs) between two groups. Then we developed the risk signature with all overall survival related GID-lncRNAs with least absolute shrinkage and selection operator (LASSO) Cox regression. The functions of the GID-lncRNAs were partly interpreted by enrichment analysis. We finally validated the effectiveness of the risk signature in prognosis prediction and medication guidance.

Results: We developed a seven-lncRNAs (LINC00460, AL139351.1, AC156455.1, AL035446.1, LINC02471, AC022509.2, and LINC01606) risk signature and divided all samples into high-risk and low-risk groups. Patients in high-risk group were in more severe clinicopathologic status (higher tumor grade, pathological stage, T stage, and more metastasis) and were deemed to have less survival time and lower survival rate. The efficacy of prognosis prediction was validated by receiver operating characteristic analysis. Enrichment analysis revealed that the lncRNAs in the risk signature mainly participate in regulation of cell cycle, DNA replication, material metabolism, and other vital biological processes in the tumorigenesis of ccRCC. Moreover, the risk signature could help assess the possibility of response to precise treatments.

Conclusion: Our study combined the somatic mutation profiles and the expression profiles of ccRCC for the first time and developed a GID-IncrRNAs based risk signature for prognosis predicting and therapeutic scheme deciding. We validated the efficacy of the
risk signature and partly interpreted the roles of the seven lncRNAs composing the risk signature in ccRCC. Our study provides novel insights into the roles of genomic instability derived lncRNAs in ccRCC.

**Keywords:** clear cell renal cell carcinoma (ccRCC), genomic instability (GI), somatic mutation profile, long non-coding RNA (lncRNA), risk signature, prognosis predicting, therapeutic scheme deciding

**INTRODUCTION**

Renal cell carcinoma (RCC) is one of the most common cancer types in urinary system, which originates from the renal epithelium and accounts for about 2% of all kinds of cancers diagnoses and deaths worldwide. The average annual incidence and death cases of RCC are about 295,000 and 134,000, respectively, and the incidence rate has been increasing over time (1). Clear cell renal cell carcinoma (ccRCC) is the main type of RCC and occupies about 80% - 90% of all RCC cases.

With the development of targeted therapy, immunotherapy, and other newly applied therapies, the clinical outcomes of a portion of patients have been improved. Whereas, according to the observations of genomic studies, there is overt molecular and cellular heterogeneity among ccRCC patients, which could contribute to the heterogeneous outcomes (2, 3). Thus, individualized evaluation and outcome prediction are in urgent need.

Genomic instability (GI) is a hallmark of most cancer, which arises from mutations and results in the occurrence of cancers (4). GI is a major cause of tumor heterogeneity within and between tumors (5). Moreover, it is broadly recognized that GI is closely related with the progression and prognosis of tumors (6–9).

Long non-coding RNA (lncRNA) is a kind of cellular transcripts that is larger than 200 nt and does not code for proteins, which mainly functions by transcription regulating, nuclear domain organizing, and proteins or RNA molecules regulating (10). Researchers have clarified that non-coding RNAs (ncRNAs) play indispensable roles in maintaining genomic stability as well as in the progression and invasion of cancers. Single nucleotide variants (SNVs) is the most frequently occurred mutation in tumors and most known cancer-related SNVs are related to the aberrant function of ncRNAs, especially lncRNAs (11, 12). Meanwhile, SNVs could regulate the expression level of corresponding ncRNAs in return (12).

The conception of GI is composed of three categories: instability of chromosome, chromatin higher-order structure, and DNA sequence (13). A series of research have proved that lncRNAs regulates the mitotic checkpoint and centromere proteins, and thus leads to aneuploidy formation (14–16). The up-regulation of telomeric repeat-containing RNA (a kind of telomeric lncRNA) contributes to the stabilization of shortened telomeres and results in chromosomal instability and tumorigenesis (17). The disruption of topologically associated domains (TADs) usually results in the abnormally activation and rearrangements of transcription, becoming an inducement of tumors (18). Normal functioning of lncRNAs participates in maintaining the stability of TADs (19, 20). DNA damage, especially DNA double-strand breaks (DSB) repair was closely related to tumorigenesis. In the processes of DSB repair, damage-induced lncRNA is regarded as a vital regulator in DSB misrepair, which would lead to GI and carcinogenesis (21, 22).

The heterogeneity of ccRCC is widely acknowledged, and the roles of GI in ccRCC have been broadly studied (23–26). While the role of GI-derived lncRNAs (GID-lncRNAs) in ccRCC has rarely been reported. It would be helpful to score tumors with GID-lncRNAs as the prognosis and therapeutic strategies may differ quite a lot from each other. In the present study, we attempted to integrate the expression profiles and somatic mutation profiles of ccRCC patients to construct a GID-lncRNA based risk signature for diagnosis prediction and therapies decision in ccRCC patients.

**MATERIALS AND METHODS**

**Study Design**

Here, we firstly illustrated the overall design and procedures of the research (Figure 1).

**Data Collection**

We collected the somatic mutation profiles, transcriptome profiles and clinical information of all ccRCC patients recorded in the database of The Cancer Genome Atlas Program (TCGA, https://portal.gdc.cancer.gov/) on 16th September, 2020. The research included the data of all 539 ccRCC tumor samples. The data of somatic mutations contains the cumulative number, mutation site, and mutation type in each sample. The data of transcriptome profile contains the expression level of detected RNAs in each sample. From the clinical information, we selected age, gender, follow-up time, survival status, tumor grade, pathological stage, TNM stage for analyses (information of lymphatic metastasis was not analyzed as it is missing in most cases and is not routinely assessed as an important criterion for prognosis predicting in ccRCC). As short follow-up period usually means inaccurate conclusions, we discarded the cases of follow-up period less than 3 months in cox regressions and survival analysis concerning follow-up time.

**Identification of the Genomic Instability Derived lncRNAs**

The somatic mutation profiles of 336 cases were available and all cases were included in this part of analysis. Firstly, we calculated the cumulative number of somatic mutations for each patient. Then, we divided the patients into genomically stable (GS) group...
FIGURE 1 | Flow chart of the design and overall procedures of our research.
and genomically unstable (GU) group after ranking all patients according to the cumulative number of somatic mutations. Patients with top 25% numbers of somatic mutations were defined as GU group, and with last 25% numbers were defined as GS group. Finally, we performed differentially expressed (DE) analysis on all lncRNAs between the two groups. The analysis was conducted using Wilcoxon test with limma package (27) under R programming environment. The cut-off criteria for statistically significant difference were decided as false discovery rate (FDR) adjusted \( p < 0.05 \) and \(|\log\text{fold change} (\text{FC})| > 1\). The identified DE-lncRNAs were regarded as GID-lncRNAs.

**Identification of Overall Survival Related GID-lncRNAs**

Of all GID-lncRNAs, overall survival (OS) related genes usually perform critical functions in the onset and progression of tumors, as well as make decisive difference on prognosis. Thus, we performed time-dependent univariate Cox regression with survival R package to extract OS-related GID-lncRNAs. The cut-off criterion for statistically significant correlations with OS was decided as \( p < 0.05 \). After discarding cases with follow-up period less than 3 months, 491 cases were included in this part of analysis.

**Development of the GID-lncRNAs Based Risk Signature for Prognosis Prediction**

The same 491 cases were included for constructing the risk signature. We divided all tumor cases into a training dataset and a testing dataset for developing and validating the risk signature. The cases were divided randomly according to a proportion of 7:3 (70% for training dataset and 30% for testing dataset, 377 cases in training dataset and 114 cases in testing dataset). We performed chi-square test to make sure that the training dataset and testing dataset were divided without bias.

Least absolute shrinkage and selection operator (LASSO) Cox regression was applied for develop a GID-lncRNAs based risk signature. The LASSO Cox regression would pick out variables for constructing the signature and give them coefficients. The GID-lncRNAs based risk signature was constructed as follow:

\[
\text{Risk score} = \beta_1 \text{expression level of lncRNA}_1 + \beta_2 \text{expression level of lncRNA}_2 + \ldots + \beta_n \text{expression level of lncRNA}_n
\]

where \( \beta_n \) is the regression coefficient of each variable.

In both of the training dataset and the testing dataset, we computed the risk score for each patient according to the risk signature and then divided the patients into high-risk group and low-risk group from the median value of the risk score.

**Analysis of the Mutation Profiles of the Two Risk Groups**

In order to assess the degree of GI and predict the prognostic outcomes of ccRCC patients with GID-lncRNAs, we have successfully developed the risk signature and divided patients into high-risk and low-risk groups. It is expected that patients in high-risk group are at GU condition. In order to confirm the supposition, we compared the mutation profiles of the two groups with maftools R package (28). All 336 cases with mutation profiles were included in this part.

**Verification of the Effectiveness in Prognosis Predicting of the Risk Signature**

After the development of the risk signature, we have to assess its reliability and robustness in estimating the prognostic outcomes of patients. The effectiveness of the signature was validated from the following 4 aspects:

(i) Overall survival analysis was conducted in training and testing datasets respectively to explore if the survival rate or survival time was significantly different between high-risk and low-risk groups. We conducted survival analysis using Kaplan-Meier method with a two-sided log-rank test (with survival R package). 377 cases were included in training dataset and 114 cases were included in testing dataset.

(ii) Receiver operating characteristic (ROC) analysis was conducted in training and testing datasets respectively to evaluate the efficiency of the risk signature in predicting the survival status using survivalROC R package. 377 cases were included in training dataset and 114 cases were included in testing dataset.

(iii) Inter-group differences of clinicopathologic features were analyzed with chi-square test for exploring whether higher risk score is corresponding to more severe clinicopathologic status. After excluding cases included missing data in tumor grade, pathological stage, or TNM stage, 457 cases were included.

(iv) Univariate and multivariate Cox regression analyses were performed to assess if the risk signature could work as independent prognostic predictor of survival in ccRCC patients. 491 cases were included.

**Function Predicting of IncRNAs Included in the Risk Signature With Enrichment Analysis**

lncRNAs do not code proteins themselves, but work through regulating protein-coding genes. In order to explore the potential function of the lncRNAs involved in the risk signature in ccRCC, we calculated the Pearson’s correlation coefficients between the lncRNAs and all mRNAs in the transcriptome profile to evaluate the co-expression relationships between lncRNAs and mRNAs. Then we extracted the top-300 related mRNAs for each lncRNA and conducted Kyoto Encyclopedia of Genes and Genomes (KEGG) (29) enrichment analysis on these related mRNAs, respectively. The cut-off criterion for significantly enriched items was decided as \( p < 0.05 \). The analysis was conducted using clusterProfiler R package (30).

**Efficacy Prediction of Precise Treatments With the Risk Signature**

In addition of predicting the prognostic outcome of ccRCC patients, the risk signature would be more serviceable if it
could provide guidance for deciding treatment selections. With the development of precision medicine, ccRCC patients are given more opportunities and choices for curing or improving outcomes. We selected several targets of immunotherapy and targeted therapy approved by Food and Drug Administration (FDA) for analysis. The included targets of precise treatment are listed as follow: mTOR, KIT, PD-1, PD-L1, PDGFRα, PDGFRβ, VEGFR1, VEGFR3, FLT3, RET, MET. We applied differentially expressed analysis for these targets between high-risk group and low-risk group to explore whether the expression level of these targets for precise treatments were related to different risk groups. The criteria for DE-genes were set as FDR adjusted $p < 0.05$ and $|\text{logFC}| > 1$.

### Efficacy Prediction of Immunotherapy With the Risk Signature Using Tumor Mutation Burden Analysis

Immunotherapy is a breakthrough for the treatment of ccRCC, but the overall response rate of PD-1/PD-L1 inhibitors is not satisfactory. It is certified that tumor mutation burden (TMB) could effectively predict the efficacy of immunotherapy of tumors as a biomarker (31). We calculated the TMB value (mutations per million bases) for each patient and compared the TMB values between high-risk and low-risk groups by t-test to explore whether the risk signature could help predict the response to immunotherapies targeting PD-1/PD-L1.

### RESULTS

#### Identification of GID-IncRNAs With Differentially Expressed Analysis

After computing the number of somatic mutations, patients were divided into GS-group and GU-group (The two groups contained 85 patients respectively, the ID and mutation number of patients are available in Table S1). We then performed DE analysis on all IncRNAs between GS-group and GU-group. We identified 46 DE-IncRNAs in all, which were regarded as functioning in GI (that is, GID-IncRNAs). Sixteen GID-IncRNAs were up-regulated in GU-group and 30 GID-IncRNAs were down-regulated in GU-group. The expression profiles of the GID-IncRNAs were shown in Figure 2A and the details (expression level, logFC, $p$ value, FDR value) were given in Table S2.

#### Identification of OS-Related GID-IncRNAs

Time-dependent univariate Cox regression recognized 9 OS-related IncRNAs from all 46 GID-IncRNAs (Figure 2B). The official gene names of the 9 OS-related IncRNAs were LINC00460, AL139351.1, AC156455.1, AL035446.1, LINCO2471, LINCO1234, AC022509.2, MIR222HG, and LINCO1606.

#### Development of the GID-IncRNAs Based Risk Signature

Before developing the risk signature, we have divided all samples (with transcriptome profiles, follow-up time, and survival status) into training dataset and testing dataset. Chi-square test confirmed that there is no significant difference in clinical features between the two datasets. The information of patients in the two datasets and results of chi-square test are shown in Table 1.

We developed the risk signature in the training dataset. All 9 OS-related IncRNAs were involved in LASSO Cox regression to construct the risk signature for predicting the prognostic outcomes of ccRCC patients. While constructing the risk signature, LINCO1234 and MIR222HG were eliminated by LASSO Cox regression.

The GID-IncRNA based risk signature was given as follow:

\[
\text{Risk score} = (0.0186884492327243 \\
\quad \times \text{expression level of } LINC00460) \\
\quad + (0.163927492372108 \times \text{expression level of } AL139351.1) \\
\quad + (0.145677628024267 \times \text{expression level of } AC156455.1) \\
\quad + (0.0813180428494581 \times \text{expression level of } AL035446.1) \\
\quad + (-0.0101523795313971 \times \text{expression level of } LINCO2471) \\
\quad + (0.00453936726148382 \times \text{expression level of } AC022509.2) \\
\quad + (0.019535978614558 \times \text{expression level of } LINCO1606)
\]

The detailed information of the 7 IncRNAs was provided in Table 2. Of the 7 IncRNAs composing the risk signature, 6 have positive coefficients and one has a negative coefficient. The up-regulation of IncRNAs with positive coefficients means worse outcome, that is, these IncRNAs may function as risky factors in ccRCC patients. Oppositely, IncRNA with negative coefficient may act as a protective factor.

For the subsequent analyses, we calculated the risk score for each patient with our risk signature and ranked patients according to their risk scores in training dataset and testing dataset, respectively. Then, patients were classified into high-risk group and low-risk group according to the median value of the risk score as a threshold (0.321 in training dataset and 0.329 in testing dataset). Samples in training dataset and testing dataset, their expression profile of the seven IncRNAs, as well as their risk scores and risk groups were given in Table S3.

#### Analysis of the Mutation Profiles of the Two Risk Groups

Figures 3A–C showed the landscape of the mutation profiles of ccRCC patients. According to different classified categories, missense mutation is the most frequently occurred type of mutations in ccRCC, and the amount of single nucleotide polymorphism (SNP) is significantly larger than that of insertion (INS) or deletion (DEL). VHL is the most frequently mutated gene in ccRCC, occupying almost 50% of all patients.

Figure 3D showed the mutation profiles of high-risk patients and low-risk patients separately. Mutations were more frequently occurred in high-risk group. Meanwhile, the mutation of several genes is rarely observed in low-risk group but frequently observed in high-risk group, for example, KDM5C. More types

---

*Yang et al.* Genomic Instability Derived IncRNAs
of mutations were observed in high-risk group. The analysis intuitively reflected the differences of mutation profiles between high-risk and low-risk groups.

Verification of the Effectiveness of Prognosis Prediction of the Risk Signature

(i) OS analysis in training dataset and testing dataset indicated that the outcome of high-risk ccRCC patients identified with our risk signature was significantly poorer than low-risk patients ($p = 1.01E-6$ and 0.001, respectively, Figures 4A, B). In training dataset, the 5-year survival rate of patients was about 48% in high-risk group, and 74% in low-risk group. In testing dataset, the 5-year survival rate was 43% and 78%, respectively.

(ii) In ROC analysis, the areas under the curve (AUC) of training dataset and testing dataset were 71.1% and 71.3%, respectively (Figures 4C, D), indicating the satisfactory robustness of the risk signature in prognosis predicting.

(iii) Chi-square test between high-risk and low-risk groups validated that the portion of patients with higher tumor grade, pathological stage, T stage, and distant metastasis...
were significantly higher in high-risk group than that of low-risk group (Table 3, the p values were 4.27E-8, 2.41E-10, 1.00E-8, and 1.81E-4, respectively).

(iv) Univariate and multivariate Cox regression analyses identified the risk signature as an independent risk factor for ccRCC patients (Figures 4E, F), which means the risk score calculated with our risk signature could predict the outcomes of ccRCC patients independent of the clinicopathologic features of tumor grade, pathological stage, T stage, and distant metastasis.

Function Predicting of IncRNAs Included in the Risk Signature With Enrichment Analysis

Figure 5 exhibits the top-10 enriched KEGG-terms of KEGG enrichment on the co-expressed genes of the seven IncRNAs in the risk signature (Details and all terms of the results of KEGG enrichment analysis are available in Table S4). LINC00460 is closely related to signal pathways of “Cell cycle”, “DNA replication”, “p53 signaling pathway”, and “Mismatch repair”. AL139351.1 is involved in signal pathways concerning material metabolism and energy cycle. AC156455.1 is related to “RNA degradation”, “Drug metabolism”, and “Mismatch repair”. AL035446.1 takes part in signal pathways of “Cell cycle”, “Drug metabolism”, and “Mismatch repair”. AC022509.2 is related to “NF-kappa B signaling pathway”, “TNF signaling pathway”, “Apoptosis”, and “PD-L1 expression and PD-1 checkpoint pathway in cancer”. LINC01606 plays roles in “mTOR signaling pathway”, “Platinum drug resistance”, and “Drug metabolism”.

According to the results of KEGG enrichment analysis, we could conclude that the seven IncRNAs are involved in several biological themes closely related to the development and progression of tumors, such as cell cycle, DNA replication, and mismatch repair. Meanwhile, these IncRNAs may play important roles in material metabolism. Moreover, the functions of the IncRNAs have enriched in several widely admitted tumor-related signal pathways, such as “NF-kappa B signaling pathway”, “p53 signaling pathway, mTOR signaling pathway, and TNF signaling pathway. Most importantly, the aberrant regulation of these

---

**TABLE 1 | Clinical information of patients in training and testing dataset and chi-square test between two groups.**

| Covariates          | Total  | Training dataset | Testing dataset | p-value |
|---------------------|--------|------------------|-----------------|---------|
| Survival status, no (%) | Alive | 340(69.25)       | 258(68.44)      | 82(71.93) | 0.55   |
|                      | Dead   | 151(30.75)       | 119(31.56)      | 32(28.07) |        |
| Age, no (%)          | <=65   | 328(66.8)        | 251(66.58)      | 77(67.54) | 0.94   |
|                      | >65    | 163(33.2)        | 126(33.42)      | 37(32.46) |        |
| Gender, no(%)        | Female | 168(34.22)       | 133(35.28)      | 35(30.7)  | 0.43   |
|                      | Male   | 323(65.78)       | 244(64.72)      | 79(69.3)  |        |
| Grade, no(%)         | G1     | 102(20.4)        | 92(23.9)        | 103(90.8) | 0.73   |
|                      | G2     | 212(43.18)       | 159(42.18)      | 53(46.49) |        |
|                      | G3     | 196(39.92)       | 150(39.79)      | 46(40.35) |        |
|                      | G4     | 67(13.65)        | 54(14.32)       | 13(11.4)  |        |
|                      | Gx     | 6(1.22)          | 5(1.33)         | 1(0.88)   |        |
| Stage, no(%)         | Stage I| 246(50.1)        | 188(49.87)      | 58(50.88) | 0.45   |
|                      | Stage II| 53(10.79)       | 39(10.34)       | 14(12.28) |        |
|                      | Stage III| 111(22.61)    | 82(21.75)       | 29(25.44) |        |
|                      | Stage IV| 78(15.89)       | 68(17.51)       | 12(10.53) |        |
|                      | Stage x| 30(6.1)          | 20(5.3)         | 10(8.8)   |        |
| T group, no(%)       | T1     | 252(51.32)       | 193(51.19)      | 59(51.75) | 0.66   |
|                      | T2     | 65(13.24)        | 47(12.47)       | 18(15.79) |        |
|                      | T3     | 165(33.6)        | 129(34.22)      | 36(31.58) |        |
|                      | T4     | 9(1.83)          | 8(2.12)         | 1(0.88)   |        |
| Metastasis, no(%)    | M0     | 390(79.43)       | 296(78.51)      | 94(82.46) | 0.08   |
|                      | M1     | 75(15.27)        | 64(16.98)       | 11(9.65)  |        |
|                      | Mx     | 26(5.3)          | 17(4.51)        | 9(7.89)   |        |

---

**TABLE 2 | Information of the seven GID-IncRNAs composing the risk signature.**

| Gene Symbol | Ensembl ID | Genomic location | Coefficient in the risk signature |
|-------------|------------|------------------|----------------------------------|
| LINC00460   | ENSG0000023532 | chr13:106,374,477-106,384,411 | 0.018688449 |
| AL139351.1  | ENSG00000276923 | chr20:48,024,788-48,074,227 | 0.163927492 |
| AC156455.1  | ENSG00000256546 | chr12:122,063,306-122,068,616 | 0.145677628 |
| AL035446.1  | ENSG00000234147 | chr6:140,807,603-140,898,430 | 0.08138043 |
| LINC02471   | ENSG00000223914 | chr12:40,155,757-40,211,419 | -0.0105238 |
| AC022509.2  | ENSG00000256234 | chr12:61,211,164-61,355,856 | 0.004539367 |
| LINC01606   | ENSG00000253301 | chr8:57,142,659-57,244,924 | 0.019539797 |
lncRNAs may contribute to the resistance towards chemotherapy and immunotherapy.

**Application of the Risk Signature in Predicting The Efficacy of Precise Treatments**

DE analysis found the significantly different expression level of KIT and PD-1 between two risk groups (Figure 6A). PD-1 was up-regulated in the high-risk group (logFC = 0.55, FDR = 2.17E-5) and KIT was down-regulated in the high-risk group (logFC = -1.92, FDR = 1.34E-5). The results hint that patients in high risk group might respond better to treatments targeting PD-1 and worse to treatments targeting KIT.

**Efficacy Prediction of Immunotherapy Using Tumor Mutation Burden Analysis**

We calculated the TMB value for each patient and compared the inter-group difference of TMB value with t-test. The average TMB value in high-risk group was significantly higher than that in low-risk group. The TMB value was 1.25 in high-risk group and 1.00 in low-risk group (p = 0.019). Figure 6B exhibited the difference of TMB between two groups (one sample in high-risk group was omitted in the figure as its TMB value was too large). The results indicated a potential higher response rate towards immunotherapy in patients of the high-risk group classified by our risk signature.
FIGURE 4 | Validation of the GID-lncRNAs based risk signature. (A) Survival analysis in training dataset. (B) Survival analysis in testing dataset. (C) ROC analysis for evaluating the predictive efficiency of the risk signature in the training dataset. (D) ROC analysis for evaluating the predictive efficiency of the risk signature in the testing dataset. (E) Results of Univariate Cox regression. (F) Results of Multivariate Cox regression.
TABLE 3 | Clinical features of patients in high-risk and low-risk groups and chi-square test between two groups.

| Covariates                  | Total | High-risk | Low-risk | p-value |
|-----------------------------|-------|-----------|----------|---------|
| Survival status, no (%)     |       |           |          |         |
| Alive                       | 310(67.83) | 128(55.51) | 184(80.00) | 3.70E-8 |
| Dead                        | 147(32.17) | 101(44.49) | 46(20.00)  |         |
| Age, no (%)                 |       |           |          |         |
| <=65                        | 303(66.3)  | 145(63.60) | 158(69.00) | 0.23    |
| >65                         | 154(33.7)  | 83(36.40)  | 71(31.00)  |         |
| Gender, no(%)               |       |           |          |         |
| Female                      | 153(33.5)  | 48(21.19)  | 105(50.7)  | 5.00E-8 |
| Male                        | 304(66.5)  | 179(78.89) | 125(49.3)  |         |
| Grade, no(%)                |       |           |          |         |
| G1                          | 7(1.55)   | 1(0.44)    | 6(2.61)    | 4.27E-8 |
| G2                          | 198(43.23) | 75(33.04)  | 123(53.48) |         |
| G3                          | 187(40.92) | 100(44.05) | 87(37.83)  |         |
| G4                          | 6(1.22)   | 5(2.24)    | 1(0.44)    |         |
| Stage, no(%)                |       |           |          |         |
| Stage I                     | 225(49.23) | 80(35.23)  | 145(63.04) | 2.41E-10|
| Stage II                    | 47(10.28)  | 19(8.37)   | 28(12.17)  |         |
| Stage III                   | 109(23.65) | 75(33.04)  | 34(14.78)  |         |
| Stage IV                    | 76(16.63)  | 53(23.35)  | 23(10.00)  |         |
| T group, no(%)              |       |           |          |         |
| T1                          | 231(50.55) | 84(37.00)  | 147(63.91) | 1.00E-8 |
| T2                          | 68(12.69)  | 28(12.33)  | 30(13.04)  |         |
| T3                          | 159(34.79) | 109(48.02) | 50(21.74)  |         |
| T4                          | 9(1.97)   | 6(2.64)    | 3(1.30)    |         |
| Metastasis, no(%)           |       |           |          |         |
| M0                          | 383(83.81) | 175(77.09) | 208(90.43) | 1.81E-4 |
| M1                          | 74(16.19)  | 52(22.91)  | 22(9.57)   |         |

DISCUSSIONS

In the present study, we integrated the analysis of the somatic mutation profiles and the transcriptome profiles of ccRCC patients to develop a GID-lncRNAs based risk signature for predicting the prognostic outcomes and deciding therapeutic strategies for ccRCC patients. We obtained the expression profiles, somatic mutation profiles, as well as clinical information of all ccRCC patients from TCGA database. We analyzed the somatic mutation profiles and classified patients into GS group and GU group. Differentially expressed analysis of transcriptome profiles between GS and GU groups identified GID-lncRNAs. Univariate Cox regression recognized 9 OS-related GID-lncRNAs and LASSO Cox regression developed a 7-lncRNAs risk signature for prognosis prediction. Using the risk signature, we classified all patients into high-risk and low-risk groups for subsequent validation and interpretation. Landscape of the mutation profiles showed the general information of somatic mutations in ccRCC patients and differences between the two risk groups. Survival analysis proved a worse prognosis in high-risk group and ROC analysis confirmed the satisfactory accuracy of prognosis predicting. Chi-square test between two risk groups validated that patients in high-risk group were in more severe clinicopathologic conditions. Cox regression proved the risk score calculated by our risk signature as an independent prognostic predictor for predicting the overall survival of ccRCC patients. KEGG enrichment analysis on co-expressed genes of the seven lncRNAs in the risk signature explored the potential role of these lncRNAs in ccRCC. The seven lncRNAs may play crucial roles in cell cycle, DNA replication, mismatch repair, and material metabolism in the development and progression of ccRCC. Finally, we attempted to predict the efficacy of precise treatments with our risk signature. DE analysis between the two groups found higher expression level of PD-1 and low expression level of KIT in high-risk group, that is, patients in high-risk group might response better to treatments targeting PD-1 and worse to treatments targeting KIT. TMB analysis detected a significant higher average TMB value in high-risk group, hinting a possibility of better response to immunotherapy targeting PD-1 and PD-L1 in high-risk group.

Up to now, the roles of lncRNAs in inducing GI in ccRCC have rarely been reported. We designed and performed the present study to screen out GID-lncRNAs in ccRCC and develop a GID-lncRNAs based risk signature for prognosis prediction and therapies decision. Our risk signature is composing of seven lncRNAs: LINC00460, AL139351.1, AC156455.1, AL035446.1, LINC02471, AC022509.2, and LINC01606.

The functions of LINC00460 have been clarified in multiple kinds of tumors. In esophageal squamous cell carcinoma (ESCC), cAMP-response element binding protein binding protein (CBP) and EP300 up-regulates the expression of LINC00460 through binding to the promoter of LINC00460 and regulating its chromatin architecture. The up-regulated LINC00460 acts as an oncogene in ESCC by regulating cell proliferation, cell cycle and apoptosis in tumor cells (32). In non-small cell lung cancer (NSCLC), LINC00460 induces epithelia-mesenchymal transition and promotes cell migration as well as invasion in tumor cells without influence the cell proliferation (33, 34). The roles of carcinogenesis of LINC00460 were also reported in nasopharyngeal carcinoma (35), meningioma (36), colorectal cancer (37, 38), gastric cancer (GC) (39, 40), and breast cancer (41). Moreover, LINC00460 is reported to promote the resistance to anticarcinogens. In colorectal cancer, the up-regulation of LINC00460 leads to oxaliplatin resistance in patients with TP53 mutations (42). In NSCLC, LINC00460 promotes the resistance to gefitinib resistance through sponging miR-769-5p. The role of LINC00460 has never been reported in ccRCC before. Our research has found its potential function of regulating cell cycle, DNA replication, mismatch repair, and drug resistance.
in ccRCC. LINC02471 has been reported as a risk factor in thyroid carcinoma. The knockdown of LINC02471 increases the expression of miR-375, which would inhibit the proliferation and invasion and promote the apoptosis of tumor cells (43). The function of LINC01606 has been reported in GC. The up-regulation of LINC01606 in GC leads to activation of Wnt/β-catenin and promotes the invasion and metastasis of the tumor (44). The functions of AC022509.2, AL139351.1, AC156455.1, and AL035446.1 have never been reported in tumors. Our research proved their relationships with the OS of ccRCC patients and partly inferred their functions in ccRCC with enrichment analysis. The roles of these lncRNAs in tumorigenesis of ccRCC need to be further explored in experimental studies.

Risk signature has been broadly used in prognosis prediction in tumors. Several risk signatures, including lncRNAs based risk signatures, have been developed for ccRCC and appeared satisfactory predictive effectiveness (45–48). However, the roles of GID-lncRNAs were rarely mentioned in ccRCC. Our research combined the somatic mutation profiles and transcriptome profiles of ccRCC for the first time to identify GI-related lncRNAs and develop a risk signature for prognosis predicting and treatment deciding accordingly. Following a series of analyses, we have developed the risk signature successfully, validated its effectiveness in prognosis prediction and medication guidance, and partly clarified the functions of the lncRNAs participating in the risk signature. Our study provides novel insight to the influence of GI in ccRCC.

Nonetheless, we have to acknowledge some limitations of our study. Firstly, the effectiveness of our risk signature has only been validated in the TCGA cohort as we failed to obtain a valid external testing dataset containing the expression levels of all
Intronic non-coding RNAs composing the risk signature. We would like to collect ccRCC samples by ourselves in the following clinical work and further validate the credibility of our risk signature in the future. Secondly, the roles of the seven lncRNAs in the risk signature have not been clearly clarified. More experimental and clinical studies are needed in the future.

CONCLUSIONS

The present study integrated the somatic mutation profiles and the transcriptome profiles of ccRCC for the first time and developed a genomic instability derived lncRNAs based risk signature for prognosis predicting and therapeutic scheme deciding. We validated the reliability of the risk signature and partly interpreted the roles of the seven lncRNAs included in the risk signature in ccRCC. Our study provides novel insights into the relationships between genomic instability and lncRNAs and the roles of genomic instability derived lncRNAs in ccRCC.

DATA AVAILABILITY STATEMENT

Publicly available datasets were analyzed in this study. This data can be found here: https://portal.gdc.cancer.gov/.

AUTHOR CONTRIBUTIONS

HY and XX contributed equally to this work. HY and XX conceived, designed, and conducted the study, as well as wrote the manuscript. All authors reviewed the manuscript and participated in the language modification. All authors contributed to the article and approved the submitted version.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fonc.2021.678253/full#supplementary-material

REFERENCES

1. Hsieh JJ, Purdue MP, Signoretti S, Swanton C, Albiges L, Schmiderg M, et al. Renal Cell Carcinoma. Nat Rev Dis Primers (2017) 3:17009. doi: 10.1038/nrdp.2017.9
2. Hsieh JJ, Chen D, Wang PI, Marker M, Redzematovic A, Chen YB, et al. Genomic Biomarkers of a Randomized Trial Comparing First-Line Everolimus and Sunitinib in Patients With Metastatic Renal Cell Carcinoma. Eur Urol (2017) 71(3):405–14. doi: 10.1016/j.eururo.2017.01.013
3. Creighton CJ, Morgan M, Gunaratne PH, Wheeler DA, Gibbs RA, Gordon Robertson A, et al. Comprehensive Molecular Characterization Of Clear Cell Renal Cell Carcinoma. Nature (2013) 499(7456):43–9. doi: 10.1038/nature12222
4. Negrini S, Gorgoulis VG, Halazonetis TD. Genomic Instability–An Evolving Hallmark Of Cancer. Nat Rev Mol Cell Biol (2010) 11(3):220–8. doi: 10.1038/nrm2858
5. Burrell RA, McGranahan N, Bartek J, Swanton C. The Causes And Consequences Of Genetic Heterogeneity In Cancer Evolution. Nature (2013) 501(7467):338–45. doi: 10.1038/nature12625
6. Bao S, Hu T, Liu J, Su J, Sun J, Ming Y, et al. Genomic Instability-derived Plasma Extracellular Vesicle-microRNA Signature As A Minimally Invasive Predictor Of Risk And Unfavorable Prognosis In Breast Cancer. J Nanobiotechnol (2021) 19(1):22. doi: 10.1186/s12951-020-00767-3
7. Malihi PD, Graf RP, Rodriguez A, Ramesh N, Lee J, Sutton R, et al. Single-Cell Circulating Tumor Cell Analysis Reveals Genomic Instability as a Distinctive Feature of Aggressive Prostate Cancer. Clin Cancer Res (2020) 26(15):4143–53. doi: 10.1158/1078-0432.CCR-19-4100
8. Li M, Zhang Z, Li L, Wang X. An Algorithm To Quantify Intratumor Heterogeneity Based On Alterations Of Gene Expression Profiles. Commun Biol (2020) 3(1):505. doi: 10.1038/s42255-020-01230-7
9. Suzuki K, Ohnami S, Tanabe C, Sasaki H, Yasuda J, Khati H, et al. The Genomic Damage Estimated By Arbitrarily Primed PCR DNA Fingerprinting Is Useful For The Prognosis Of Gastric Cancer. *Gastroenterology* (2003) 125 (5):1330–40. doi: 10.1016/j.gastro.2003.07.006
10. Marchese FP, Raimondi I, Huarte M I, Raimondi, Huarte M. The Multidimensional Mechanisms Of Long Noncoding RNA Function. *Genome Biol* (2017) 18(1):206. doi: 10.1186/s13059-017-1348-2
11. Cheetham SW, Grulh F, Mattick JS, Dinger ME. Long Noncoding RNAs And The Genetics Of Cancer. *Br J Cancer* (2013) 108(12):2419–25. doi: 10.1038/bjc.2013.233
12. Lin C, Yang L. Long Noncoding RNA in Cancer: Wiring Signaling Circuitry. *Trends Cell Biol* (2018) 28(4):287–301. doi: 10.1016/j.tcb.2017.11.008
13. Guo F, Li L, Yang W, Cui J. Long Noncoding RNAs: A Resident Staff Of Genomic Instability Regulation In Tumorigenesis. *Cancer Lett* (2021) 503:103–9. doi: 10.1016/j.canlet.2021.01.021
14. Deng X, Li S, Kong F, Ruan H, Xu Y, Zhang X, et al. Long Noncoding RNA Pith Regulates P53 Protein Stability Through GRWD1/RPL11/MDM2 Axis In Colorectal Cancer. *Theranostics* (2020) 10(1):265–80. doi: 10.7150/thno.36045
15. Liu J, Ben Q, Lu E, He X, Yang X, Ma J, et al. Long Noncoding RNA PANDAR Blocks CDKN1A Gene Transcription By Competitive Interaction With P53 Protein In Gastric Cancer. *Cell Death Dis* (2018) 9(2):168. doi: 10.1038/cr.2018.497
16. Lian Y, Yan C, Xu H, Yang J, Yu Y, Zhou J, et al. A Novel lncRNA, Linc00460 Promotes Epithelial-Mesenchymal Transition And Cell Invasion Through Regulating Epithelial-Mesenchymal Transition (EMT) In Non-Small Cell Lung Cancer. *Eur Rev Med Pharmacol* (2018) 22(4):1003–4. doi: 10.26355/eurrev_201802_14382
17. Zhang Y, Liu X, Li Q, Zhang Y. LncRNA LINC00460 Contributes to the Metastasis and Invasion of Human Gastric Cancer. *Cancer Biomark* (2020) 24(4):237–9. doi: 10.3233/CBM-182177
18. Yang et al. Genomic Instability Derived lncRNAs
19. Suzuki K, Ohnami S, Tanabe C, Sasaki H, Yasuda J, Katai H, et al. The Genetics Of Cancer. *Cancer Biomark* (2021) 78(12):3135–46. doi: 10.1158/0008-5472.CAN-17-3460
20. Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, et al. Limma Powers Differential Expression Analyses For RNA-sequencing And Microarray Studies. *Nucleic Acids Res* (2015) 43(7):e47. doi: 10.1093/nar/gkv007
21. Wang ZD, Shen LP, Chang C, Zhang XQ, Chen ZM, Li L, et al. The Genetics Of Cancer. *Cancer Lett* (2013) 108(12):2419–25. doi: 10.1038/bjc.2013.233
22. Shen L, Wang Q, Chen X, Zhang Z, et al. Increased Chromosomal Instability Characterizes Metastatic Renal Cell Carcinoma. *Transl Oncol* (2021) 14(1):100929. doi: 10.1016/j.tranon.2020.100929
23. Correa AF, Ruth KJ, Al-Saleem T, Pei J, Dulaïmi E, Kister D, et al. Overall Tumor Genomic Instability: An Important Predictor Of Recurrence-Free Survival In Patients With Localized Clear Cell Renal Cell Carcinoma. *Cancer Biol Ther* (2020) 21(5):424–31. doi: 10.1080/15384074.2020.1721251
24. Rondinelli B, Rosano D, Antonini E, Frenquelli M, Montanini L, Huang D, et al. Histone Demethylase JARID1C Inactivation Triggers Genomic Instability In Sporadic Renal Cancer. *J Clin Invest* (2015) 125(12):4625–37. doi: 10.1172/JCI81040
25. Zhang YC, Park JY, Terzo EA, Tripathi DN, Mason FM, Fahey CC, et al. SETD2 Haplosufficiency for Microtubule Methylation Is an Early Driver of Genomic Instability in Renal Cell Carcinoma. *Cancer Res* (2018) 78(12):3135–46. doi: 10.1158/0008-5472.CAN-17-3460
26. Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, et al. Limma Powers Differential Expression Analyses For RNA-sequing And Microarray Studies. *Nucleic Acids Res* (2015) 43(7):e47. doi: 10.1093/nar/gkv007
27. Mayakonda A, Lin DC, Assenov Y, Plass C, Koellner HP. Maftools: Efficient And Comprehensive Analysis Of Somatic Variants In Cancer. *Genome Res* (2018) 28(11):1747–56. doi: 10.1101/gr.239244.118
28. Ogata H, Goto S, K拊buchi W, Bono H, Kanehisa M. KEGG: Kyoto Encyclopedia of Genes and Genomes. *Nucleic Acids Res* (1999) 27(1):29–34. doi: 10.1093/nar/27.1.29
29. Yu G, Wang LG, Han Y, He QY. Cluster Profiler: an R Package For Comparing Biological Themes Among Gene Clusters. *Omnics* (2012) 16 (5):284–7. doi: 10.1089/omi.2011.0118
30. Yi M, Jiao D, Xu H, Liu Q, Zhao W, Han X, et al. Biomarkers For Predicting Efficacy Of PD-1/PD-L1 Inhibitors. *Mol Cancer* (2018) 17(1):129. doi: 10.1186/s12933-018-0864-3
31. Liu Y, Yu W, Chen X, Zhang S, Wang K, Guan X, et al. A Novel Long Noncoding RNA Linc00460 Up-Regulated By CBP/P300 Promotes Carcinogenesis In Esophageal Squamous Cell Carcinoma. *Biosci Rep* (2017) 37(5). doi: 10.1042/BSR20171019
32. Li K, Sun D, Gou Q, Ke X, Geng Y, Zuo Y, et al. Long Non-Coding RNA Linc00460 Promotes Epithelial-Mesenchymal Transition And Cell Invasion In Lung Cancer Cells. *Cancer Lett* (2018) 420:80–90. doi: 10.1016/j.clet.2018.01.060
33. Yue QY, Zhang Y, Yang J, Wang S. lncRNA LINC00460 Enhances Cell Migration And Invasion Through Regulating Epithelial-Mesenchymal Transition (EMT) In Non-Small Cell Lung Cancer. *Front Immunol* (2021) 12:684–97. doi: 10.3389/fimmu.2021.00612
34. Zhang Y, Liu X, Li Q, Zhang Y. LncRNA LINC00460 Promoted Colorectal Cancer Cell Invasion And Metastasis Via miR-939-Sp Sponging. *Cancer Manag Res* (2019) 11:1779–89. doi: 10.2147/CMAR.S192452
35. Wang F, Liang S, Liu X, Han L, Wang J, Du Q. LINC00460 Modulates KDM2A To Promote Cell Proliferation And Migration By Targeting miR-342-3p In Gastric Cancer. *Onco Targets Ther* (2018) 11:6383–94. doi: 10.2147/OTT.S169307
36. Zhang Y, Xu J, Wang H, Guo H. Downregulation of Long Noncoding RNA LINC00460 Up-regulated By CBP/P300 Promotes Epithelial-Mesenchymal Transition And Cell Invasion In Lung Cancer Cells. *Biosci Rep* (2017) 37(5). doi: 10.1042/BSR20171019
37. Yang H, Han M, Li H. Construction and Validation of an Autophagy-Related Prognostic Risk Signature for Survival Predicting in Clear Cell Renal Cell Carcinoma Patients. *Front Oncol* (2020) 10:707. doi: 10.3389/fonc.2020.00707
46. Qu L, Wang ZL, Chen Q, Li YM, He HW, Hsieh JJ, et al. Prognostic Value of a Long Non-coding RNA Signature in Localized Clear Cell Renal Cell Carcinoma. *Eur Urol* (2018) 74(6):756–63. doi: 10.1016/j.eururo.2018.07.032

47. Gui CP, Cao JZ, Tan L, Huang Y, Tang YM, Li PJ, et al. A Panel Of Eight Autophagy-related Long Non-coding RNAs Is A Good Predictive Parameter For Clear Cell Renal Cell Carcinoma. *Genomics* (2021) 113(2):740–54. doi: 10.1016/j.ygeno.2021.01.016

48. Kang B, Sun C, Gu H, Yang S, Yuan X, Ji C, et al. T1 Stage Clear Cell Renal Cell Carcinoma: A CT-Based Radiomics Nomogram to Estimate the Risk of Recurrence and Metastasis. *Front Oncol* (2020) 10:579619. doi: 10.3389/fonc.2020.579619

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2021 Yang, Xiong and Li. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.